Biomarkers Market Report 2026

Biomarkers Market Overview

• Biomarkers market size has reached to $77.42 billion in 2025 • Expected to grow to $150.52 billion in 2030 at a compound annual growth rate (CAGR) of 14.2% • Growth Driver: Elevated Prevalence Of Heart Diseases As A Catalyst For Biomarkers Market Expansion • Market Trend: Innovative Biomarker Tests Advancing Healthcare Solutions In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biomarkers Market?

Biomarkers refer to a biological molecule that is a marker for a condition, disease, or aberrant process and can be discovered in tissues, body fluids, or blood. It is used to determine how well the body responds to a disease or condition's treatment. These biomarkers have a clinical role in narrowing or guiding treatment decisions. The main types of biomarkers are biomarker of exposure and biomarker of diseases. The biomarker of exposure is a substance corresponding to the chemical that may be found in the body. When a person is exposed to chemicals by direct contact, inhaling or ingesting helps to identify them. Various technologies used for biomarkers are safety biomarkers, efficacy biomarkers, and validation biomarkers used to treat diseases such as neurological diseases, cancer, immunological diseases, cardiovascular diseases, and other. These biomarker are used by pharmaceutical companies, government and private research institutes, academic institutes, and medical device manufacturing companies for risk assessment, the development of molecular diagnostic, disease diagnosis, drug discovery and development, drug formulation, forensic application and others (DNA fingerprinting, and others).

What Is The Biomarkers Market Growth Forecast?

The biomarkers market size is expected to see rapid growth in the next few years. It will grow to $150.52 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to expansion of personalized treatment approaches, rising adoption of liquid biopsy biomarkers, increasing regulatory support for biomarker-based drugs, growth in neurological disease research, expanding collaborations between pharma and diagnostics firms. Major trends in the forecast period include increasing use of biomarkers in precision medicine, growing integration in drug discovery and development, rising adoption in oncology and chronic disease management, expansion of companion diagnostics, greater focus on early disease detection.

What Is The Driver Of The Biomarkers Market?

The increase in heart diseases is expected to propel the growth of the biomarkers market in the forecasted period. The use of biomarkers for heart disease patients has increased tremendously over the last few years. Currently, the natriuretic peptides are the most used biomarker and help in the diagnosis of patients with heart failure. Biomarkers such as circulating biomarkers with high sensitivity C-reactive protein are used for the diagnosis of heart failure. Heart disease is among leading cause of death for people of most racial and ethnic groups in the United States. The increase in heart diseases will drive the demand for biomarkers. For instance, in September 2025, according to the British Heart Foundation, a UK-based charity, across the UK, more than 7.6 million people over 4 million men and more than 3.6 million women are living with cardiovascular disease, and projections indicate that, driven by an aging population and improved survival rates, the number of affected individuals may rise by around 1 million by 2030 and by approximately 2 million by 2040. Therefore, the increase in heart diseases is propelling the growth of the biomarkers industry.

Key Players In The Global Biomarkers Market

Major companies operating in the biomarkers market are Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Global Biomarkers Market Trends and Insights

Major companies operating in the biomarker market are developing innovative products such as biomarker tests to meet larger customer bases, more sales, and increase revenue. Biomarker tests, also known as biomarker assays, are laboratory techniques or diagnostic tests that measure specific biological markers, which can include molecules, genes, proteins, or other substances, to provide information about various physiological or pathological processes in the body. For instance, in July 2023, Quest Diagnostics, a US-based medical laboratories company, launched a novel prostate cancer biomarker test. The newly introduced tissue-based test service aims to meet the urgent clinical demand for tests that can assist in distinguishing potentially aggressive cases of prostate cancer in males. Quest has created and validated this laboratory test through an intellectual property license agreement with Envision, allowing the utilization of Envision's exclusive biomarker and immunohistochemistry technology, incorporating Envision's distinct staining methods and innovative biomarkers referred to as EV1, EV2, and EV3.

What Are Latest Mergers And Acquisitions In The Biomarkers Market?

In July 2023, Biocare Medical, a US-based biotechnology company, acquired Empire Genomics for an undisclosed amount. Through this acquisition, Biocare is broadening its molecular portfolio, encompassing more than 1 million biomarkers, and introducing swift biomarker development to advance cancer research leadership. Biocare Medical's expanded molecular menu, coupled with its state-of-the-art automation platforms such as the ONCORE Pro X, will empower researchers to accelerate their work, expediting cancer diagnostics for improved patient outcomes at an unprecedented pace. Empire Genomics is a US-based biotechnology company.

What Defines the Biomarkers Market?

The biomarkers market consists of sales of molecular biomarkers, cellular biomarkers or imaging biomarkers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biomarkers Market Report 2026?

The biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.